BioSpace News Archive

Changed primary endpoint to continuous from current responder endpoint, in-line with recent FDA guidance and very similar to IW-3718 Phase IIb trial

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological products, issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced it will report second quarter 2020 financial results after the market close on Tuesday, August 11, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update. Investors inter

50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trial Subject to regulatory approval, a randomized, double-blinded, placebo-controlled, multinational Phase III part of the trial will be initiated Primary endpoint of the planned Phase III part to be 28-day all-cause mortality

Collaboration will Combine MyoKardia’s Leading Precision Cardiovascular R&D Platform with Fulcrum’s Proprietary Product Engine to Identify Targets that Modulate Gene Expression

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a second round of independent laboratory testing has confirmed the antiviral activity of WP1122 against coronavirus.

- Multiple System Atrophy (MSA) is a rare, relentlessly progressive and fatal neurodegenerative disease - Verdiperstat is a potential first-in-class, brain-penetrant inhibitor of myeloperoxidase (MPO), an enzyme implicated in neuroinflammation and neurodegeneration - Approximately 300 patients enrolled in the 48-week trial and topline data anticipated by the end of 2021 [21-July-2020]

REVEAL screening and testing service offers both COVID-19 RT PCR diagnostic tests and antibody tests

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPCF) today announced that Dr. Christopher Sorli, MD, PhD, FACE will join the Company as Chief Medical Officer, effective August 3, 2020, and will become a member of Acerus’ Senior Leadership Team. “I am very pleased to announce that Dr. Sorli is joining the Company in th

Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (" Tenzing ") (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (" Reviva ") and a California -based clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas